FUTURE OF HEALTHCARE

HealthyU Clinics Reinforces Commitment to Integrative Healthcare by Collaborating with evolvedMD

Shefali Vasave | June 07, 2022

HealthyU Clinics

Premier collaborative and proactive care provider, HealthyU has announced a collaboration with evolveMD to boost its commitment to expanding mental health care services. The partnership will enable HealthyU to leverage the VC-backed venture evolvedMD’s expertise in behavioral health to offer innovative health care in the behavioral health space. 

"HealthyU's goal is to model and advance the standard of integrative healthcare, and there isn't a partner out there with a better track record to help us realize this ambition than evolvedMD. Knowing that mental health is integral to physical health, this partnership will amplify our team's ability to treat the whole patient and increase access to top-tier care in the Valley."

Shane Speirs, MD, Chief Medical Officer at HealthyU Clinics

HealthyU launched its first clinic in Avondale in 2021, followed by a rapid scaling and expansion with six more clinics across the Valley. Patients will be able to visit an evolvedMD licensed health professional at the HealthyU clinics starting on June 23rd, 2022.

"What makes HealthyU an exceptional partner is its focus on proactive innovation in primary care. We are constantly seeking out opportunities to disrupt healthcare, and our partnership with HealthyU will enable us to disrupt from the ground up with our proven collaborative care model at their new locations. This is the first time that we can scale with a partner from the beginning, and we are looking forward to seeing how this approach allows for innovation in the integrated healthcare space."

Erik Osland, Co-Founder and Managing Partner at evolvedMD
 

Spotlight

Holland Hospital Telehealth Services keeps patients safe, healthy and at home. And easy-to-use home device combined with remote nurse monitoring and video conferencing gives patients added confidence and the family’s peace of mind. See how it works in this video.

Spotlight

Holland Hospital Telehealth Services keeps patients safe, healthy and at home. And easy-to-use home device combined with remote nurse monitoring and video conferencing gives patients added confidence and the family’s peace of mind. See how it works in this video.

Related News

HEALTH TECHNOLOGY

Henry Schein Acquires Midway Dental Supply

Henry Schein, Inc. | August 30, 2022

Henry Schein, Inc. the world’s largest provider of health care solutions to office-based dental and medical practitioners, announced the acquisition of Midway Dental Supply, a full-service dental distributor serving dental offices and dental laboratories across the Midwestern United States. Henry Schein acquired 100% of Midway Dental, which was founded in 1987 by the late Roger Abigt, and is headquartered in Livonia, Michigan. This transaction is expected to be modestly dilutive to Henry Schein’s earnings per share in fiscal year 2022 and increasingly accretive thereafter. Financial terms were not disclosed. Midway Dental’s sales from 2021 were approximately $110 million, including nearly $20 million in sales of personal protective equipment (PPE) and COVID-19 related products. Midway Dental offers a comprehensive portfolio of dental consumable merchandise, equipment, services, and education products to nearly 7,000 customers, which will be immediately consolidated into Henry Schein’s U.S. Dental business. The integration of Midway Dental’s sales and service team with Henry Schein’s network of trusted advisors will further advance the Company’s efforts to deliver customized solutions and technology-driven products and services to help our dental customers meet the needs of patients. “Over the past 35 years, Midway Dental has earned an excellent reputation within the industry, grounded by a strong commitment to customer service and industry leadership that is aligned with Henry Schein’s values-based culture and high-touch, full-service business model,” said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. “Midway Dental’s vision to establish a nationwide footprint aligns with Henry Schein’s commitment to provide the products and services customers can rely on to work more efficiently and deliver high-quality patient care more effectively.” Led by CEO Steven Kizy, Midway Dental has approximately 200 employees, including 55 sales representatives and 50 service technicians. Mr. Kizy will join Henry Schein as Vice President, Strategic Development-U.S. Dental. “As part of Henry Schein, Midway Dental will have access to new capabilities, including an expanded portfolio of solutions to serve our customers even better while offering our staff exciting new career possibilities. More specifically, Midway Dental’s customers will benefit from the vast array of Henry Schein branded products as well as the latest digital technologies that are modernizing dental practices. We are delighted to be joining forces with the world’s leading provider of dental products and services.” Mr. Kizy About Henry Schein, Inc. Henry Schein, Inc. is a solutions company for health care professionals powered by a network of people and technology. With more than 22,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites. Henry Schein operates through a centralized and automated distribution network, with a selection of more than 120,000 branded products and Henry Schein private-brand products in stock, as well as more than 180,000 additional products available as special-order items. A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 32 countries and territories. The Company's sales reached $12.4 billion in 2021, and have grown at a compound annual rate of approximately 12.5 percent since Henry Schein became a public company in 1995.

Read More

HEALTH TECHNOLOGY

Sense and TECOmedical Sign Distribution Agreement for Germany, Austria, Switzerland

Sense Biodetection | September 02, 2022

Global molecular diagnostics innovator, Sense Biodetection announced it has entered into a strategic agreement with TECOmedical for the non-exclusive distribution of Sense’s Veros COVID-19, the first test on the rapid, instrument-free, point-of-care Veros molecular testing platform. The self-contained, single-use Veros COVID-19 product produces PCR-quality results in about 15 minutes, unconstrained by a reader or need for external power. TECOmedical, a Eurobio Scientific Company, is a leading specialty medical distributor with proven success developing new markets with innovative technology. Effective immediately in Germany and Austria, and pending regulatory approval in Switzerland, the agreement is the latest in Sense’s planned EU distribution partnerships as it commercializes its Veros platform. “We are delighted to partner with TECOmedical to bring Veros COVID-19 to the market, building on the impressive reputation that TECOmedical has established with their customers,” stated Ryan Roberts, Chief Commercial Officer of Sense. “We’re optimistic that by adding the instrument-free Veros COVID-19 to their diagnostic portfolio, TECOmedical’s customers will be able to take advantage of a laboratory-quality molecular test that can enable improved access and faster diagnosis, helping them to provide exceptional care for their patients right at the point of use.” “We are always looking for innovative technologies that address an unmet need. Being able to offer an instrument free, PCR-quality result in minutes right at the Point of Care reflects our commitment to customers to bring solutions that help them overcome limitations of existing technologies and improve care. We are excited to launch Veros COVID-19 now and are eagerly anticipating an expanded Veros test menu in the future.” Marieluise Wippermann, CEO of TECOmedical Veros is the first and only instrument-free, single-use, rapid, point-of-care molecular diagnostic testing platform that produces lab-quality results in about 15 minutes. Using a proprietary, rapid molecular amplification technology, Veros aims to help to improve access to rapid, highly accurate, point of care testing for many more people, and help reduce the spread of COVID-19 with faster, more precise diagnoses. Veros COVID-19’s clinical performance was established in one of the most comprehensive clinical trials in COVID-19 diagnostic testing conducted to date. The multicentre study prospectively enrolled nearly 300 evaluable subjects during both the Delta and Omicron variant surges of the pandemic. All study sites represented near-patient testing / point-of-care environments, with all test operators reporting no prior formal laboratory training or experience. 100% of operators agreed the Veros COVID-19 was easy-to-use, read and understand the results, with minimal hands-on time required from start to finish. As the virus continues to evolve, Veros COVID-19 has maintained 100% conservation in all Variants of Interest and Concern identified to date by WHO and the US CDC, including all Omicron sub-variants. About Sense Biodetection Sense Biodetection is a global molecular diagnostics company focused on empowering patients and transforming healthcare access and affordability by bringing lab-quality results through easy-to-use, rapid, disposable molecular tests without the constraints of an instrument. The company's Veros product platform will enable widespread testing to enhance patient access, improve patient health and lower systemic healthcare costs. Backed by respected investors, such as Koch Disruptive Technologies, Cambridge Innovation Capital, Earlybird Health and Mercia Asset Management, Sense has launched its first product, Veros COVID-19, and is growing rapidly while building a portfolio of tests for other diseases. About TECOmedical The Swiss-based TECOmedical Group, a Eurobio Scientific company, with subsidiaries in Germany and Austria is a leading provider of in-vitro specialty test systems in medical diagnostic, based on Immunosorbent, Immunofluorescence and Molecular methodologies.

Read More

HEALTHTECH SECURITY

Medtronic Extravascular ICD meets global pivotal clinical trial's safety and effectiveness endpoints

Medtronic plc | August 29, 2022

Medtronic plc a global leader in healthcare technology, today announced that its investigational EV ICD™ System – a first-of-its-kind defibrillator with the lead placed under the breastbone, outside of the heart and veins – achieved a defibrillation success rate of 98.7% and met its safety endpoints in a global clinical trial. Findings from the Extravascular Implantable Cardioverter Defibrillator Pivotal Study were presented as late-breaking science today at the European Society of Cardiology Congress 2022 in Barcelona and simultaneously published in The New England Journal of Medicine. Worldwide, the EV ICD system is investigational and not yet approved for sale or distribution. The Medtronic EV ICD system is designed to treat dangerously fast heart rhythms that can lead to sudden cardiac arrest while avoiding certain risks of traditional, transvenous ICDs because its lead (thin wire) is placed outside the heart and veins, under the breastbone (sternum) using a minimally invasive approach. Placing the lead in this location is designed to help avoid long-term complications that may be associated with leads in the heart and veins, such as vessel occlusion and risks for blood infections. The lead is connected to a device that is implanted below the left armpit. Clinical trial participants received the same therapies provided by traditional ICDs, including defibrillation, anti-tachycardia pacing (ATP), and back-up pacing therapies with this single implanted device that is similar in size, shape, and longevity to traditional ICDs. "We are very encouraged by the high defibrillation effectiveness and strong safety profile of the EV ICD system seen in the study, as we look to deliver less-invasive treatment options for patients at risk of sudden cardiac arrest. These results demonstrate the potential for this novel technology to be used as a safe, successful approach for patients with life-threatening arrhythmias." Ian Crozier, MB, CHB, M.D., Christchurch Hospital, Christchurch, New Zealand, who presented the results at ESC Congress 2022 At six months, 25 major complications were observed in 23 of 316 patients who underwent an implant attempt (7.3%). Twenty-nine patients experienced inappropriate shocks (9.7%, average 10.6 months follow up), most commonly due to P-wave oversensing, which was more frequent in patients implanted early in the study and less frequent among patients implanted later in the study. "These pivotal data mark the start of a new era in ICD therapy for patients who are at significant risk of dangerously fast heart rhythms," said Alan Cheng, M.D., chief medical officer of the Cardiac Rhythm Management business, which is part of the Cardiovascular Portfolio at Medtronic. "Today's findings are an important clinical milestone toward our goal of delivering a one-system, one-procedure extravascular ICD solution that prevents sudden cardiac arrest while improving the patient experience with a smaller device and moving the lead out of the veins and placing it under the breastbone. The EV ICD system retains the benefits of a completely extravascular system while providing ATP, pause prevention pacing and low defibrillation energy." The EV ICD Pivotal study is a prospective, multicenter, single-arm, non-randomized, pre-market clinical study that assessed the safety and effectiveness of the Medtronic EV ICD system for patients at risk of sudden cardiac death. The EV ICD Pivotal study enrolled 356 patients at 46 sites in 17 countries in North America, Europe, the Middle East, Asia, Australia and New Zealand. Medtronic has received FDA approval for a Continued Access Study while the agency reviews the company's EV ICD pre-market application. About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for all. In everything we do, we are engineering the extraordinary.

Read More